BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:NEUROBiOGEN readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies NEUROBiOGEN's drugs run\, from Cl
 inicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07009171-730@assetmemo.bio
DTSTAMP:20261121T005717Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Tisolagiline: Phase 2 readout est. (NCT07009171)
DESCRIPTION:Tisolagiline\, phase 2\, Obesity.\nStudy: Study to Evaluate the
  Efficacy and Safety of KDS2010 in Overweight or Obese Patients\nEstimated
  primary completion: 31 January 2027. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/tisolagiline#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT07009171
URL:https://assetmemo.bio/drug/tisolagiline#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07027072-730@assetmemo.bio
DTSTAMP:20261121T005717Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Tisolagiline: Phase 2 readout est. (NCT07027072)
DESCRIPTION:Tisolagiline\, phase 2\, Alzheimer's Disease.\nStudy: Study to 
 Evaluate the Efficacy and Safety of KDS2010 in Patients With Alzheimer's D
 isease With Mild Cognitive Impairment and Mild Dementia Due to Alzheimer's
  Disease\nEstimated primary completion: 30 June 2027. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/tisolagiline#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT07027072
URL:https://assetmemo.bio/drug/tisolagiline#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
